LCM
PROF

Legato Capital Management’s Profound Medical PROF Stock Holding History

Legato Capital Management’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,668
Closed -$784K – 856
2025
Q4 		$784K Buy
+99,668
New +$641K 0.07% 422

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $395M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Legato Capital Management's PROF Position: Q1 2026 in Review

Legato Capital Management sold out of Profound Medical (PROF) in Q1 2026, closing a stake of 99,668 shares — an estimated $784K sold.

Legato Capital Management first reported a position in PROF in Q4 2025 and held it in 1 quarter. The position peaked at $784K in Q4 2025. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Legato Capital Management reported no remaining Profound Medical position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 99,668 Profound Medical shares in Q1 2026, an estimated $784K.
  • Legato Capital Management first reported a position in Profound Medical in Q4 2025 and held it in 1 quarter.
  • Legato Capital Management's Profound Medical position peaked at $784K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.